Skip to content

We want to clarify that IG International does not have an official Line account at this time. We have not established any official presence on Line messaging platform. Therefore, any accounts claiming to represent IG International on Line are unauthorized and should be considered as fake.
CFDs are complex instruments. 70% of retail client accounts lose money when trading CFDs, with this investment provider. You can lose your money rapidly due to leverage. Please ensure you understand how this product works and whether you can afford to take the high risk of losing money.
CFDs are complex instruments. 70% of retail client accounts lose money when trading CFDs, with this investment provider. You can lose your money rapidly due to leverage. Please ensure you understand how this product works and whether you can afford to take the high risk of losing money.

Cronos sells Whistler Medical shares to Aurora Cannabis

The marijuana producer sells its stake in Whistler Medical Marijuana to rival Aurora.

Marijuana plant after Cronos sells Whistler Medical shares Source: Bloomberg
Cannabis Medical cannabis Aurora Cannabis Cannabidiol Brand

Cronos Group has sold its 19% of shares in Whistler Medical Marijuana to rival cannabis maker Aurora. Shares of the Canadian cannabis company fell 2% after the news.

Why is Cronos selling Whistler shares to Aurora?

Cronos has sold its shares in Whistler Medical, a medical marijuana company that produces 18 strains of pot and also sells CBD oil, to capitalise on the pot boom across the US and Canada. As the drug is legalised across much of North America, the growth in cannabis has led many marijuana companies to consolidate as a result.

In this strategic deal, Aurora will pay Cronos C$175 million for the stake in Whistler Medical. In return for the stake, Cronos will receive Aurora stock worth C$26.6 million dollars. Cronos will also receive an extra C$7.6 million shares based on the achievement of certain milestones after the acquisition.

Mike Gorenstein, chief executive officer (CEO), of Cronos, thanked Whistler for their partnership after selling the shares.

‘We'd like to thank and congratulate Whistler for their partnership over the past two years,’ said Gorenstein.

‘Whistler's commitment to creating high-quality products and establishing a premium brand has generated value for consumers and investors alike. We are proud to have been part of their growth and look forward to their progress through this venture,’ added Gorenstein.

Aurora CEO, Terry Booth, spoke about the expansion efforts the company wants to implement with its purchase of Whistler.

‘Applying certain of our best practices to the Whistler cultivation protocols, we anticipate an increase in capacity of the Pemberton facility beyond the stated 5,000 kg annual production target,’ said Booth in a statement.

What’s next for Cronos stock?

Cronos stock rose briefly before falling after Aurora acquired its shares of Whistler Medical. Though some investors say marijuana is a good investment and are bullish on the commodity, there is also concern about an oversaturation in the market. Cronos and Aurora hope that this consolidation will encourage investors to continue to invest in marijuana.


This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.